Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has synthesized molecular glue compounds targeting protein cereblon (CRBN) acting as CRBN/target protein interaction inducers reported to be useful for the treatment of cancer.
Researchers at Monash University in Melbourne have discovered that transcription factors Ikaros and Aiolos work by binding to AP-1 transcriptional complexes and driving their transcription, which regulates thousands of genes in the human body.
Kronos Bio Inc. has nominated a new development candidate, KB-9558, which targets the lysine acetyltransferase (KAT) domain of p300, a critical node of the IRF4 transcription regulatory network (TRN), which is a key driver in multiple myeloma.
In a recent publication in Scientific Reports, researchers at City of Hope and collaborators presented a novel CS1 bsAb, called CS1-dbBiTE, conjugating an intact anti-CS1 antibody (elotuzumab) and an anti-human OKT3 antibody at their respective hinge regions using Click chemistry.
Multiple studies at the 65th American Society of Hematology Annual Meeting 2023 have the potential to change the treatment paradigm for first-line treatment of multiple myeloma.
Norcantharidin is an active ingredient in Chinese traditional medicine that has activity against several cancer types, but its application is limited in the clinic due to toxicity and a narrow treatment window. Researchers from Tongji University and the Shanghai Institute of Materia Medica have recently described a derivative of norcantharidin – DCZ-5417 – for the potential treatment of multiple myeloma (MM).
GSK plc is looking at a comeback for Blenrep (belantamab mafodotin) as an interim efficacy analysis brought the company good news. Almost exactly a year ago, phase III confirmatory study data for the already-approved multiple myeloma drug fell short of the U.S. FDA’s accelerated approval requirements, so the agency asked GSK to take the drug off the market for the indication.
Disrupting apoptosis is a mechanism that cancerous cells use to avoid being killed; this can be performed by overexpressing pro-survival factors, such as induced myeloid leukemia cell differentiation protein Mcl-1. Researchers from Abbvie Inc. have recently published preclinical data on a potent and selective Mcl-1 inhibitor, ABBV-467, for the treatment of hematologic cancers.
If there had been any lingering market concerns following the temporary partial clinical hold earlier this year for Arcellx Inc.’s multiple myeloma CAR T-cell therapy, CART-ddBCMA, they were likely put to rest as partner Gilead Sciences Inc.’s Kite unit expanded the scope of the firms’ late 2022 collaboration to include lymphomas. At the same time, Kite exercised an option to negotiate a license for Arcellx’s ARC-Sparx program, ACLX-001, in multiple myeloma.
Israeli biotech Biolinerx Ltd. will hand off the rights to its stem cell mobilizer, motixafortide, in Asia to China’s Gloria Biosciences Co. Ltd. via an out-licensing deal worth up to $280 million, news that sent stocks soaring nearly 13% on Oct. 31.
